chapter  9
Nurse-led pathway for patients with HER2 positive breast cancer receiving Trastuzumab (Herceptin)
Pages 21

This chapter provides an in-depth case study of a nurse-led clinic. It focuses on the development, implementation, ongoing evaluation and latest update of a nurse-led pathway for Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer patients receiving Trastuzumab (Herceptin). Although the primary focus was on early-stage disease, the pathway also includes some patients with metastatic disease. The various stages of the pathway development will be explained and supported by relevant evidence from the appropriate time period.